Reaction to results · all yearsrose on day 0 in 0 of 1 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 11 Aug 2026 | -2.1% | -5.7% | +2.2% | 0.9× |
| Average | -2.1% | -5.7% | +2.2% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSV| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVDelivery percentage
Over the last 20 sessions FERMENTA settled 45.3% of its traded quantity, which is above average for an NSE equity. Its one-year average is 52.4%, so recent sessions are running 7.2 points lower than usual.
What delivery percentage measuresScan the whole market on delivery
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +2.15% | +18.81% | +13.37% | +54.49% | — | — |
Valuation
CSVOwnership
CSVQuarterly results · consolidated
CSV| Q1 FY27 | |
|---|---|
| Revenue (₹ Cr) | 121.8 |
| YoY chg | — |
| Net profit (₹ Cr) | 9.5 |
| YoY chg | — |
| Net margin | 7.8% |
| EPS | 3.34 |
Shareholding over time
CSVOne quarter on file; a trend needs two.
- Promoter
- 64.09%
- Public
- 33.36%
- Promoter change
- —
- Filed
- 4 Aug 2026
- FII
- 0.37%
- DII
- 0.04%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV| Q1 FY27 | Trend | |
|---|---|---|
| Revenue from operations | 121.8 | |
| Other income | 4.4 | |
| Total income | 126.2 | |
| Total expenses | 111.5 | |
| └ Finance costs | 2.5 | |
| └ Depreciation | 5.2 | |
| Profit before tax | 14.7 | |
| Tax expense | 5.2 | |
| Net profit | 9.5 | |
| EPS | 3.40 | |
| Net margin | 7.82% | |
| PBT margin | 12.06% | |
| Tax rate | 35.12% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 11 Aug 2026.
1 quarter on file; a year-on-year comparison needs five.
FERMENTA at a glance
- FERMENTA closed at ₹569.45 on 6 Oct 2026, +2.15% on the day.
- Delivery was 25.5% of traded quantity on 6 Oct 2026, the 5th percentile of its own 117 sessions with a reading (20-session average 45.3%, 1-year average 52.4%).
- Market capitalisation is ₹1,676 crore, with no positive trailing earnings for a P/E.
- Q1 FY27 results (consolidated, filed 11 Aug 2026): revenue ₹122 crore, net profit ₹10 crore; the price moved -2.1% on the first session after.
- Promoters held 64.09% at 3 Aug 2026.
About
CSVPrices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE